The Prurigo Nodularis pipeline report from DelveInsight provides comprehensive insights into 5+ companies and 5+ pipeline drugs in the Prurigo Nodularis pipeline landscape. It includes clinical and nonclinical stage products in the pipeline drug profiles. It also assesses therapeutics based on product type, stage, route of administration, and molecule type.
Some of the Important Finding from the Prurigo Nodularis Pipeline Report
Sanofi and Regeneron Pharmaceuticals initiated a Phase III clinical trial in January 2020 to assess the efficacy and safety of dupilumab in Prurigo Nodularis patients.
Chugai Pharmaceutical and Galderma Pharma S.A. announced in July 2016 that they had signed a global licence deal for the drug “Nemolizumab” (CIM331), which is currently in Phase III clinical trials for Prurigo Nodularis.
Kiniksa Pharmaceuticals announced the results of Prurigo Nodularis phase II clinical trials for Vixarelimab (KPL-716) in April 2020.
Some pipeline therapies such as Haduvio, and others are in the Phase II/III of Prurigo Nodularis clinical trials.
Key players in Prurigo Nodularis pipeline landscape include Sanofi, Regeneron Pharmaceuticals, Chugai Pharmaceutical, Galderma Pharma S.A., Kiniksa Pharmaceuticals, Trevi Therapeutics, and others.
For more information, request sample @ Prurigo Nodularis Treatment
Prurigo Nodularis: Overview
Prurigo Nodularis (PN) is a chronic, inflammatory skin condition marked by pruritic nodules that have a significant negative influence on one’s quality of life. A cutaneous reaction pattern caused by vicious cycles of chronic itch followed by recurrent scratching is assumed to constitute the pathogenesis of Prurigo Nodularis. The specific pathophysiology of Prurigo Nodularis is still unknown.
Prurigo Nodularis Treatment
Treatment for Prurigo Nodularis demands a diverse approach. Patients should be educated on how to reduce scratching of lesions, how to diagnose and treat underlying causes of pruritus, and how to diagnose and treat any psychiatric disorders linked to scratching and picking at skin. Topical and systemic treatments are aimed at breaking the itch-scratch cycle.
Prurigo Nodularis Pipeline Analysis: Drug Profiles
Dupilumab: Regeneron/Sanofi
Product Description
Dupilumab is an interleukin-4 (IL-4) receptor alpha antagonist. It is an immunoglobulin G4 subclass human monoclonal antibody that inhibits IL-4 and interleukin-13 (IL-13) signalling by binding to the IL-4 receptor alpha subunit, which is shared by the IL-4 and IL-13 receptor complexes.
Phase III
NCT04202679 (PRIME 2): Sanofi launched a Phase 3 randomised, double-blind, placebo-controlled, multi-center, parallel group study in January 2020 in collaboration with Regeneron Pharmaceuticals to assess the efficacy and safety of dupilumab in patients with Prurigo Nodularis who are inadequately controlled on topical prescription therapies or for whom those therapies are not advisable.
Get in touch to know more about PN @ Prurigo Nodularis ICD 10
Prurigo Nodularis Pipeline Therapies and Key Companies
Vixarelimab: Kiniksa Pharmaceuticals
Haduvio: Trevi Therapeutics
Nemolizumab (CIM331): Chugai Pharmaceutical
Prurigo Nodularis Therapeutics Assessment
By Product Type
Monotherapy
Combination Therapy
By Stage
Discovery
Pre-Clinical
Phase I
Phase II
Pre-registration
By Route of Administration
Inhalation
Intravenous
Oral
Subcutaneous
By Molecule Type
Small Molecule
Stem Cell Therapy
Gene Therapy
Targets
Immune System
Multiple Kinase
Protease
By Mechanism of Action
Protease Inhibitors
Immunomodulatory
Multiple Kinase Inhibitors
Scope of the Report
Coverage: Global
Prurigo Nodularis Key Players: Kiniksa Pharmaceuticals, Trevi Therapeutics, Regeneron Pharmaceuticals, Sanofi, Chugai Pharmaceutical, Galderma Pharma S.A.,among others
Prurigo Nodularis Pipeline Therapies: Vixarelimab, Haduvio, Dupilumab, Nemolizumab (CIM331), and others
Table of Contents
1.
Introduction
2.
Executive Summary
3.
4.
Prurigo Nodularis- Analytical Perspective In-depth Commercial Assessment
5.
Prurigo Nodularis Pipeline Therapeutics
6.
Prurigo Nodularis Late Stage Products (Phase III)
7.
Prurigo Nodularis Mid Stage Products (Phase II/III)
8.
Prurigo Nodularis Mid Stage Products (Phase II)
9.
Prurigo Nodularis Early Stage Products (Phase I/II and Phase I)
10.
Prurigo Nodularis Pre-clinical and Discovery Stage Products
11.
Prurigo Nodularis Therapeutic Assessment
12.
Prurigo Nodularis Inactive Products
13.
Prurigo Nodularis Company-University Collaborations (Licensing/Partnering) Analysis
14.
Prurigo Nodularis Key Companies
15.
Prurigo Nodularis Key Products
16.
Prurigo Nodularis- Unmet Needs
17.
Prurigo Nodularis- Market Drivers and Barriers
18.
Prurigo Nodularis- Future Perspectives and Conclusion
19.
Prurigo Nodularis Analyst Views
20.
Appendix
21.
About DelveInsight
For rich insights into Healthcare and Pharmaceutical News, visit Pharma, Healthcare and Biotech Blog Posts
Key questions answered in the Prurigo Nodularis Pipeline Report
What are the treatment options for Prurigo Nodularis?
How many pharmaceutical companies are working on therapies for Prurigo Nodularis?
What are the most popular therapies from each of these companies?
How many Prurigo Nodularis drugs does each company generate in total?
How many Prurigo Nodularis pipeline drugs are in the early stages of development, mid-stage development, or late-stage development?
How many of the in-development therapies can be used alone or in combination with other treatments?
What are the most important industry-industry and industry-academy cooperation, mergers and acquisitions, and licencing practises that have an impact on Prurigo Nodularis?
Related Reports
Pruritus Pipeline Insights
Get comprehensive analysis of Pruritus pipeline therapies and key companies including Cara Therapeutics, Regeneron, AbbVie, Atridia, Saniona, DermaXon, Trevi Therapeutics, among others.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Shruti ThakurEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: www.delveinsight.com/